Polymeric Nanoparticle Drug Delivery Technologies for Oral Delivery Applications

Overview

Journal Expert Opin Drug Deliv

Publisher Informa Healthcare

Specialty Pharmacology

Date 2015 Mar 28

PMID 25813361

Citations 62

Authors

Eric M Pridgen

Frank Alexis

Omid C Farokhzad

Affiliations

Soon will be listed here.

Abstract

Introduction: Many therapeutics are limited to parenteral administration. Oral administration is a desirable alternative because of the convenience and increased compliance by patients, especially for chronic diseases that require frequent administration. Polymeric nanoparticles (NPs) are one technology being developed to enable clinically feasible oral delivery.

Areas Covered: This review discusses the challenges associated with oral delivery. Strategies used to overcome gastrointestinal (GI) barriers using polymeric NPs will be considered, including mucoadhesive biomaterials and targeting of NPs to transcytosis pathways associated with M cells and enterocytes. Applications of oral delivery technologies will also be discussed, such as oral chemotherapies, oral insulin, treatment of inflammatory bowel disease, and mucosal vaccinations.

Expert Opinion: There have been many approaches used to overcome the transport barriers presented by the GI tract, but most have been limited by low bioavailability. Recent strategies targeting NPs to transcytosis pathways present in the intestines have demonstrated that it is feasible to efficiently transport both therapeutics and NPs across the intestines and into systemic circulation after oral administration. Further understanding of the physiology and pathophysiology of the intestines could lead to additional improvements in oral polymeric NP technologies and enable the translation of these technologies to clinical practice.

Citing Articles

Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC - What is Coming Next?.

Bohley M, Leroux J Adv Sci (Weinh). 2024; 11(33):e2400843.

PMID: 38884149 PMC: 11434117. DOI: 10.1002/advs.202400843.

Cellular response of keratinocytes to the entry and accumulation of nanoplastic particles.

Martin L, Simpson K, Brzezinski M, Watt J, Xu W Part Fibre Toxicol. 2024; 21(1):22.

PMID: 38685063 PMC: 11057139. DOI: 10.1186/s12989-024-00583-9.

Recent Progress in the Oral Delivery of Therapeutic Peptides and Proteins: Overview of Pharmaceutical Strategies to Overcome Absorption Hurdles.

Mehrotra S, Kalyan Bg P, Nayak P, Joseph A, Manikkath J Adv Pharm Bull. 2024; 14(1):11-33.

PMID: 38585454 PMC: 10997937. DOI: 10.34172/apb.2024.009.

State of the art in pediatric nanomedicines.

Abedin S, Adeleke O Drug Deliv Transl Res. 2024; 14(9):2299-2324.

PMID: 38324166 DOI: 10.1007/s13346-024-01532-x.

Exploiting Apical Sodium-Dependent Bile Acid Transporter (ASBT)-Mediated Endocytosis with Multi-Functional Deoxycholic Acid Grafted Alginate Amide Nanoparticles as an Oral Insulin Delivery System.

Razmjooei M, Hosseini S, Yousefi G, Golmakani M, Eskandari M Pharm Res. 2023; 41(2):335-353.

PMID: 38114803 DOI: 10.1007/s11095-023-03641-7.

References

Boddupalli B, Mohammed Z, Nath R, Banji D . Mucoadhesive drug delivery system: An overview. J Adv Pharm Technol Res. 2012; 1(4):381-7. PMC: 3255397. DOI: 10.4103/0110-5558.76436. View

Bies C, Lehr C, Woodley J . Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev. 2004; 56(4):425-35. DOI: 10.1016/j.addr.2003.10.030. View

Lai S, Wang Y, Wirtz D, Hanes J . Micro- and macrorheology of mucus. Adv Drug Deliv Rev. 2009; 61(2):86-100. PMC: 2736374. DOI: 10.1016/j.addr.2008.09.012. View

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

Adson A, Burton P, Raub T, Barsuhn C, Audus K, Ho N . Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci. 1995; 84(10):1197-204. DOI: 10.1002/jps.2600841011. View

Eldridge J, Meulbroek J, Staas J, Tice T, Gilley R . Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol. 1989; 251:191-202. DOI: 10.1007/978-1-4757-2046-4_18. View

Petrus A, Fairchild T, Doyle R . Traveling the vitamin B12 pathway: oral delivery of protein and peptide drugs. Angew Chem Int Ed Engl. 2008; 48(6):1022-8. DOI: 10.1002/anie.200800865. View

Cochran E, Musso C, Gorden P . The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005; 28(5):1240-4. DOI: 10.2337/diacare.28.5.1240. View

Roy K, Mao H, Huang S, Leong K . Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999; 5(4):387-91. DOI: 10.1038/7385. View

10.

Kotze A, Luessen H, De Boer A, Verhoef J, Junginger H . Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur J Pharm Sci. 1998; 7(2):145-51. DOI: 10.1016/s0928-0987(98)00016-5. View

11.

Borner M, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A . Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002; 38(3):349-58. DOI: 10.1016/s0959-8049(01)00371-9. View

12.

des Rieux A, Fievez V, Garinot M, Schneider Y, Preat V . Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006; 116(1):1-27. DOI: 10.1016/j.jconrel.2006.08.013. View

13.

Brayden D . Oral vaccination in man using antigens in particles: current status. Eur J Pharm Sci. 2001; 14(3):183-9. DOI: 10.1016/s0928-0987(01)00175-0. View

14.

Fowler R, Vllasaliu D, Trillo F, Garnett M, Alexander C, Horsley H . Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. Small. 2013; 9(19):3282-94. DOI: 10.1002/smll.201202623. View

15.

Tsukita S, Furuse M, Itoh M . Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001; 2(4):285-93. DOI: 10.1038/35067088. View

16.

Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters R . Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med. 2012; 18(8):1291-6. PMC: 3475749. DOI: 10.1038/nm.2866. View

17.

Lamprecht A, Schafer U, Lehr C . Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001; 18(6):788-93. DOI: 10.1023/a:1011032328064. View

18.

Huang Y, Leobandung W, Foss A, Peppas N . Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Release. 2000; 65(1-2):63-71. DOI: 10.1016/s0168-3659(99)00233-3. View

19.

Moulari B, Beduneau A, Pellequer Y, Lamprecht A . Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J Control Release. 2014; 188:9-17. DOI: 10.1016/j.jconrel.2014.05.046. View

20.

Alexis F, Pridgen E, Molnar L, Farokhzad O . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-15. PMC: 2663893. DOI: 10.1021/mp800051m. View